InnaVirVax Press Release at CROI 2013
March 17, 2013
Shahin Gharakhanian statement in the latest Press Release from InnaVirVax issued during the Conference on Retroviruses, 3-6 March 2013, Atlanta GA, USA.
Reference: Katlama Ch, Launay O, Ho Tsong Fang R, Bodilis H, Calin R, Autran B, Gharakhanian S, Vieillard V, J Crouzet J, Debré P. A randomized, placebo-controlled, double-blind, phase I/IIa dose escalation study of an HIV immunotherapeutic vaccine, VAC-3S, directed to the gp41 3S motif of HIV-1. 20th Conference on Retroviruses (CROI), 2013, Atlanta GA, 3-6 March, Poster # 392. retroconference.org